Information Provided By: 
Fly News Breaks for November 19, 2019
CALA
Nov 19, 2019 | 07:03 EDT
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Calithera Biosciences with a Buy rating and $7 price target. The company's lead product, telaglenastat, is a first-in-class, small molecule, oral glutaminase inhibitor for the treatment of kidney cancer, or renal cell carcinoma, Ramakanth tells investors in a research note. The analyst adds that pivotal clinical results are expected in 2020.
News For CALA From the Last 2 Days
There are no results for your query CALA
